Efficacy and safety of low dose-steroid treatment for acute exacerbation of idiopathic interstitial pneumonia

Efficacy and safety of low dose-steroid treatment after steroid pulse therapy for acute exacerbation of idiopathic interstitial pneumonia -a pilot study- (FIT-dose Study) - FIT-dose Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1061220085

Enrollment

Registered

2023-01-22

Start date

2023-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute exacerbation of idiopathic interstitial pneumonia

Interventions

Day 1~ 3 Prednisolone 1.0mg/kg Day 4~ 10 Prednisolone 0.5mg/kg Day 11~ 17 Prednisolone 0.5mg/kg -5mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Over 18 years old 2. Witten informed consent 3. Patients with acute exacerbation of idiopathic interstitial pneumonia 4. Patients who do not require intubation or non- invasive ventilation 5. No progression of interstitial pneumonia on the 3rd day of steroid pulse therapy (methylprednisolone 1 g for 3 days)

Exclusion criteria

Exclusion criteria: 1. Patients receiving immunosuppressants 2. Patients with interstitial pneumonia other than idiopathic interstitial pneumonia (e.g. collagen vascular disease, pneumoconiosis, drug-induced pneumonia, radiation pneumonitis, sarcoidosis, hypersensitivity pneumonia) 3. Patients with serum creatinine over 1.5 times the upper limit of normal 4. Patients with serious complications 5. Patients who lack the ability to consent 6. Patients with hypersensitivity to prednisolone 7. Patients receiving desmopressin acetate hydrate 8. Pregnancy 9. Patients judged by the principal investigator or co-investigator to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Treatment success rate at day 18 from start of study treatment	—

Secondary

Measure	Time frame
1. Ratio of cases that meet the following conditions on day 18 of study treatment compared to the end date of steroid pulse therapy - Decrease in PaO2/FiO2 ratio due to interstitial pneumonia - Worsen of chest X-ray or CT findings due to interstitial pneumonia - Increase in the level of CRP - Increase in the level of KL-6 - Worsen of mMRC scale 2. Duration until discharge after start of study treatment 3. Cumulative recurrence rate of acute exacerbations at 60 days from the start of study treatment 4. Survival rate at 60 days from start of study treatment 5. Adverse events during the study treatment 6. Adverse events related to steroids at 60 days	—

Measure

Time frame

1. Ratio of cases that meet the following conditions on day 18 of study treatment compared to the end date of steroid pulse therapy - Decrease in PaO2/FiO2 ratio due to interstitial pneumonia - Worsen of chest X-ray or CT findings due to interstitial pneumonia - Increase in the level of CRP - Increase in the level of KL-6 - Worsen of mMRC scale 2. Duration until discharge after start of study treatment 3. Cumulative recurrence rate of acute exacerbations at 60 days from the start of study treatment 4. Survival rate at 60 days from start of study treatment 5. Adverse events during the study treatment 6. Adverse events related to steroids at 60 days

—

Contacts

Public ContactMasuda Takeshi

Hiroshima University Hospital

ta-masuda@hiroshima-u.ac.jp+81-822575196

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026